Drug-Induced Neutropenia and Agranulocytosis

Drug-induced neutropenia and agranulocytosis are serious and potentially life-threatening complications of pharmacotherapy. The aim of the review was to systematise and analyse scientific literature on the prevalence, risk factors, pathogenesis, clinical picture, methods of prevention and treatment of drug-induced neutropenia and agranulocytosis, and medicinal products that most often lead to their development. The analysis revealed that one of the major reasons of drug-induced neutropenia and agranulocytosis is the use of cytotoxic drugs (alkylating agents, antimetabolites, taxanes), non-steroidal anti-inflammatory drugs, antibiotics, antiplatelet, antithyroid, antirheumatic, antiarrhythmic, and antipsychotic drugs. The incidence of drug-induced neutropenia and agranulocytosis is generally low—from 3 to 16 cases per 1 million patients annually. The main risk factors for the development of these conditions include old age, female sex, history of chemotherapy or radiation therapy, malnutrition, and comorbidities. The symptoms in patients with neutropenia and agranulocytosis regardless of etiology can include fever, chills, apathy, myalgia, weakness, pharyngitis, gingivitis, sinusitis, stomatitis, bronchitis, and sepsis. There are no practical methods for early diagnosis or prevention of drug-induced neutropenia and agranulocytosis. Successful management of these conditions relies on timely identification and immediate withdrawal of the potential causative drug. Prevention of chemotherapy-associated neutropenia may consist in reducing the dose of the chemotherapeutic agent. Practicing physicians should be aware of the risk of drug-induced neutropenia and agranulocytosis. It is important to raise awareness among healthcare professionals of the methods of diagnosis and prevention of these conditions, as well as specific aspects of managing patients with these conditions.

agranulocytosis, neutropenia, drugs, adverse drug reactions

1. Tisdale JE, Miller DA. Drug-induced diseases: prevention, detection, and management. 3rd ed. Bethesda: ASHP; 2018.

2. Naletov AA, Shmalts EA, Zotov PB, Fedorov NM, Zaynetdinova DZ, Fadeeva AI. Neutropenic fever as prognostic complication of polychemotherapy. Palliativnaya meditsina i reabilitatsiya = Palliative Medicine and Rehabilitation. 2019;(3):37–41 (In Russ.)

3. Andrès E, Maloisel F. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol. 2008;15(1):15–21. https://doi.org/10.1097/MOH.0b013e3282f15fb9

4. Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med. 2007;146(9):657–65. https://doi.org/10.7326/0003-4819-146-9-200705010-00009

5. Huber M, Andersohn F, Bronder E, Klimpel A, Thomae M, Konzen C, et al. Drug-induced agranulocytosis in the Berlin case-control surveillance study. Eur J Clin Pharmacol. 2014;70(3):339–45. https://doi.org/10.1007/s00228-013-1618-1

6. Ibáñez L, Vidal X, Ballarín E, Laporte JR. Populationbased drug-induced agranulocytosis. Arch Intern Med. 2005;165(8):869–74. https://doi.org/10.1001/archinte.165.8.869

7. Andrès E, Maloisel F. Antibiotic-induced agranulocytosis: a monocentric study of 21 cases. Arch Intern Med. 2001;161(21):2619. https://doi.org/10.1001/archinte.161.21.2619

8. Wenham C, Gadsby K, Deighton C. Three significant cases of neutropenia with etanercept. Rheumatology (Oxford). 2008;47(3):376–7. https://doi.org/10.1093/rheumatology/kem332

9. Hartmann EL, Gatesman M, Roskopf-Somerville J, Stratta R, Farney A, Sundberg A. Management of leukopenia in kidney and pancreas transplant recipients. Clin Transplant. 2008;22(6):822–8. https://doi.org/10.1111/j.1399-0012.2008.00893.x

10. Andrès E, Mourot-Cottet R. Idiosyncratic drug-induced severe neutropenia and agranulocytosis: state of the art. In: Guenova M, Balatzenko G, eds. Hematology—Latest Research and Clinical Advances. IntechOpen; 2018. https://doi.org/10.5772/intechopen.78769

11. Andrès E, Zimmer J, Mecili M, Weitten T, Alt M, Maloisel F. Clinical presentation and management of drug-induced agranulocytosis. Expert Rev Hematol. 2011;4(2):143–51. https://doi.org/10.1586/ehm.11.12

12. Andrès E, Maloisel F, Kurtz JE, Kaltenbach G, Alt M, Weber JC, et al. Modern management of non-chemotherapy druginduced agranulocytosis: a monocentric cohort study of 90 cases and review of the literature. Eur J Intern Med. 2002;13(5):324–8. https://doi.org/10.1016/s0953-6205(02)00085-7

13. Andrès E, Kurtz JE, Perrin AE, Dufour P, Schlienger JL, Maloisel F. Haematopoietic growth factor in antithryoid-drug-induced agranulocytosis. QJM. 2001;94(8):423–8. https://doi.org/10.1093/qjmed/94.8.423

14. Babkina AS, Golubev AM, Sundukov DV, Bashirova AR, Golubev MA. Clozapine: mechanisms of toxicity and side effects. General Reanimatology. 2018;14(2):35–45 (In Russ.) https://doi.org/10.15360/1813-9779-2018-2-35-45

15. Liu ZC, Uetrecht JP. Metabolism of ticlopidine by activated neutrophils: implications for ticlopidine-induced agranulocytosis. Drug Metab Dispos. 2000;28(7):726–30.

16. Starkebaum G, Kenyon CM, Simrell CR, Creamer JI, Rubin RL. Procainamide-induced agranulocytosis differs serologically and clinically from procainamide-induced lupus. Clin Immunol Immunopathol. 1996;78(2):112–9. https://doi.org/10.1006/clin.1996.0020

17. Fitchen JH, Koeffler HP. Cimetidine and granulopoiesis: bone marrow culture studies in normal man and patients with cimetidine-associated neutropenia. Br J Haematol. 1980;46(3):361–6. https://doi.org/10.1111/j.1365-2141.1980.tb05982.x

18. Cherepanova VV, Mikhailova ZD, Mikhailova JV, Sinkova VV. Neutropenia: this old problem is a new reading. Hematologist tips for the cardiologist. Kardiologiya: novosti, mneniya, obuchenie = Cardiology: News, Opinions, Training. 2019;7(1):47–50 (In Russ.)] https://doi.org/10.24411/2309-1908-2019-11006

19. Andrès E, Mourot-Cottet R, Maloisel F. Diagnosis and management of idiopathic drug-induced and severe neutropenia and agranulocytosis: What should the lung specialist know? J Lung Health Dis. 2018;1(1):31–8.

20. Andrès E, Cottet-Mourot R, Keller O, Serraj K, Vogel T. Clinical articularities of drug-induced agranulocytosis or severe neutropenia in elderly patients. J Hematol Thrombo Dis. 2016;4(2):1000235. https://doi.org/10.4172/2329-8790.1000235

21. Andrès E, Mourot-Cottet R, Maloisel F, Séverac F, Keller O, Vogel T, et al. Idiosyncratic drug-induced neutropenia and agranulocytosis. QJM. 2017;110(5):299–305. https://doi.org/10.1093/qjmed/hcw220

22. Coates TD. Drug-induced neutropenia and agranulocytosis. UpToDate; 2020. https://www.uptodate.com/contents/druginduced-neutropenia-and-agranulocytosis

23. Shapiro S, Issaragrisil S, Kaufman DW, Anderson T, Chansung K, Thamprasit T, et al. Agranulocytosis in Bangkok, Thailand: a predominantly drug-induced disease with an unusually low incidence. Aplastic Anemia Study Group. Am J Trop Med Hyg. 1999;60(4):573–7. https://doi.org/10.4269/ajtmh.1999.60.573

24. Williams DP, Pirmohamed M, Naisbitt DJ, Uetrecht JP, Park BK. Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. Mol Pharmacol. 2000;58(1):207–16. https://doi.org/10.1124/mol.58.1.207

25. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038–51. https://doi.org/10.1200/JCO.2000.18.16.3038

26. Legge SE, Hamshere ML, Ripke S, Pardinas AF, Goldstein JI, Rees E, et al. Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia. Mol Psychiatry. 2017;22(10):1502–8. https://doi.org/10.1038/mp.2016.97

27. Risk of agranulocytosis and aplastic anaemia in relation to use of antithyroid drugs. International Agranulocytosis and Aplastic Anaemia Study. BMJ. 1988;297(6643):262–5. https://doi.org/10.1136/bmj.297.6643.262

28. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993;329(3):162–7. https://doi.org/10.1056/NEJM199307153290303

29. Takata K, Kubota S, Fukata S, Kudo T, Nishihara E, Ito M, et al. Methimazole-induced agranulocytosis in patients with Graves’ disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid. 2009;19(6):559–63. https://doi.org/10.1089/thy.2008.0364

30. Hermans P. Haematopoietic growth factors as supportive therapy in HIV-infected patients. AIDS. 1995;9 Suppl 2:S9–14.

31. Maloisel F, Andrès E, Kaltenbach G, Noel E, MartinHunyadi C, Dufour P. Prognostic factors of hematological recovery in life-threatening nonchemotherapy drug-induced agranulocytosis. A study of 91 patients from a single center. Presse Med. 2004;33(17):1164–8. https://doi.org/10.1016/s0755-4982(04)98884-7

32. Ibáñez L, Sabaté M, Ballarín E, Puig R, Vidal X, Laporte JR. Use of granulocyte colony-stimulating factor (G-CSF) and outcome in patients with non-chemotherapy agranulocytosis. Pharmacoepidemiol Drug Saf. 2008;17(3):224–8. https://doi.org/10.1002/pds.1542

33. Keisu M, Ekman E. Sulfasalazine associated agranulocytosis in Sweden 1972–1989. Clinical features, and estimation of its incidence. Eur J Clin Pharmacol. 1992;43(3):215–8. https://doi.org/10.1007/BF02333012

34. Ferretti G, Papaldo P, Cognetti F. Lineage-specific hematopoietic growth factors. N Engl J Med. 2006;355(5):526; author reply 527. https://doi.org/10.1056/NEJMc061587

35. Makarova PM, Galstyan GM, Troitskaya VV, Kuzmina LA, Drize NI, Parovichnikova EN. Use of multipotent mesenchymal stem cells for the treatment of septic shock in severe neutropenic patient. Gematologiya i transfuziologiya = Hematology and Transfusiology. 2015;60(4):48–52 (In Russ.)

36. Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33(28):3199–212. https://doi.org/10.1200/JCO.2015.62.3488

37. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Executive summary: clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):427–31. https://doi.org/10.1093/cid/ciq147

38. Bagrova SG. Granulocyte colony-stimulating factors in prevention of febrile neutropenia. Effektivnaya farmakoterapiya = Effective Pharmakotherapy. 2015;2(31):6–15 (In Russ.)]

39. Andrès E, Maloisel F, Zimmer J. The role of haematopoietic growth factors granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the management of drug-induced agranulocytosis. Br J Haematol. 2010;150(1):3–8. https://doi.org/10.1111/j.1365-2141.2010.08104.x